Foghorn Therapeutics Reports Q3 2026 Results: Revenue Hits $83.5 Million and GAAP EPS of $1. ...
Collaboration revenue reaches $83.5 million, driving quarterly net income of $58.2 million Related Stocks: FHTX ,
Collaboration revenue reaches $83.5 million, driving quarterly net income of $58.2 million Related Stocks: FHTX ,